Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chugai Pharmaceutical Co's Other Stockholders Equity for the quarter that ended in Jun. 2026 was $12,612 Mil.
Chugai Pharmaceutical Co's quarterly Other Stockholders Equity
declined
from Dec. 2025 ($12,993 Mil) to Mar. 2026 ($12,022 Mil) but then
increased
from Mar. 2026 ($12,022 Mil) to Jun. 2026 ($12,612 Mil).
Chugai Pharmaceutical Co's annual Other Stockholders Equity
increased
from Dec. 2023 ($11,290 Mil) to Dec. 2024 ($12,362 Mil) and
increased
from Dec. 2024 ($12,362 Mil) to Dec. 2025 ($12,993 Mil).
Chugai Pharmaceutical Co Other Stockholders Equity Related Terms
Chugai Pharmaceutical Co Other Stockholders Equity Historical Data
* Premium members only.
The historical data trend for Chugai Pharmaceutical Co's Other Stockholders Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chugai Pharmaceutical Co Other Stockholders Equity Chart
What does a Other Stockholders Equity of $12,612 Mil mean?
Chugai Pharmaceutical Co (CHGCY) has a Other Stockholders Equity of $12,612 Mil as of Jun. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Chugai Pharmaceutical Co and its competitors.
Is Chugai Pharmaceutical Co's Other Stockholders Equity too high?
Chugai Pharmaceutical Co's current Other Stockholders Equity is $12,612 Mil. Overall, Chugai Pharmaceutical Co has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Chugai Pharmaceutical Co's Other Stockholders Equity compare to LLY and JNJ?
Chugai Pharmaceutical Co's Other Stockholders Equity of $12,612 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Chugai Pharmaceutical Co and its competitors. Chugai Pharmaceutical Co's current Other Stockholders Equity is $12,612 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chugai Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co (CHGCY) is currently considered Modestly Undervalued. The stock's GF Value™ is $24.68, compared to a current price of $21.61 — trading 12.4% below its estimated fair value. The current Other Stockholders Equity is $12,612 Mil. Chugai Pharmaceutical Co's overall GF Score™ is 89/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Chugai Pharmaceutical Co (CHGCY), the current Other Stockholders Equity is $12,612 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chugai Pharmaceutical Co (CHGCY) Overvalued in 2026?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co stock appears to be undervalued.
The current stock price of $21.61 is trading 12.4% below its estimated GF Value™ of $24.68.
GuruFocus considers Chugai Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for CHGCY:
Other Stockholders Equity: $12,612 Mil
GF Value™: $24.68 vs. price of $21.61 (12.4% below fair value)
No single metric tells the full story. See the CHGCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra (hemophilia), Actemra (rheumatoid arthritis, covid), Foundayo (oral obesity pill), and Nemluvio (atopic dermatitis, prurigo nodularis).
89GF Score
Get the complete analysis for CHGCY
Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHGCY has been successfully added to your 
